From FLOW to REMODEL: Understanding Semaglutide in CKD, With Katherine Tuttle, MD

Semaglutide research keeps breaking new ground—this time in chronic kidney disease (CKD). The peptide, already known for its impact on metabolism and glucose regulation, is getting serious attention for its potential in kidney research. The FLOW trial put semaglutide under the microscope for CKD, and now the REMODEL study is set to dig even deeper.

Here’s what matters: Semaglutide isn’t just another research compound for diabetes. Researchers, led by Dr. Katherine Tuttle, are now pushing to see if it can reshape how we approach CKD progression. That’s a big shift. Traditionally, peptide research in kidney disease has lagged behind the metabolic field. FLOW changed that, showing early signals that semaglutide could do more than just manage blood sugar.

Key details from the ongoing research:

Why this is interesting: The research community is hungry for new CKD strategies. Current options are limited, and most haven’t budged in decades. Semaglutide is offering a fresh angle—targeting inflammation and metabolic dysfunction at the same time.

Big picture: If semaglutide’s benefits in CKD hold up, it could open the door to a new class of peptide-based research compounds for kidney disease. The REMODEL study will be one to watch for anyone interested in peptide innovation and renal research. More data, more opportunities for the peptide research field.